17 types of proprietary Chinese medicines have been purchased in quantity and started to be reported!

The volume of procurement of proprietary Chinese medicines in 19 provinces and regions announced last month has begun!

On October 19, Shanxi Province in the Interprovincial Alliance of Chinese Patent Medicines issued the "Notice on the Filling of Procurement Data Related to the Range of Procurement Species of the Inter-provincial Alliance of Chinese Patent Medicines" (Jinyao Zhao [2021] No.

This report will take the form of online filling, starting from tomorrow.

Time to fill in: 0:00, October 21, 2021-24:00, October 29, 2021

It is understood that the medical insurance bureaus of Ningxia and other provinces have also issued similar notifications

Procurement of Proprietary Chinese Medicines by the Inter-provincial Alliance

The inter-provincial alliance purchasing of 17 types of Chinese patent medicines is another inter-provincial alliance after Guangdong and other 7 provinces

On September 25, the Hubei Provincial Medical Insurance Bureau still announced a "Proprietary Chinese Patent Medicine Interprovincial Alliance Centralized Procurement Announcement (No.

The inter-provincial alliance of proprietary Chinese medicines consists of Hubei, Hebei, Shanxi, Inner Mongolia, Liaoning, Fujian, Jiangxi, Henan, Hunan, Hainan, Chongqing, Sichuan, Guizhou, Tibet, Shaanxi, Gansu, Ningxia, Xinjiang, Xinjiang Production and Construction Corps and other alliance regions Appoint representatives to form the Central Procurement Leading Group Office of the Inter-Provincial Alliance of Chinese Patent Medicines to implement centralized procurement of Chinese patent medicines on behalf of public medical institutions (including military medical institutions) and voluntary medical insurance designated social medical institutions and designated pharmacies in various regions.

It should be noted here that the above 19 provinces (regions) overlap with some provinces in the previous Guangdong 7-province inter-provincial alliance

The Chinese patent medicines selected in Announcement No.

Procurement rules

The "Announcement" stated that the same product group is divided into two competition units, A and B, to compete separately

Declaring companies that meet one of the following conditions enter the A competition unit, and the others enter the B competition unit:

With the declaring company as a unit, the 2020 purchase amount of all products reported by the medical institutions in the alliance area of ​​the same product group will be merged, and the amount of the declaring company that accounts for 10% or more of the total value of the same product group

Take the applicant company as the unit, merge the 2020 purchase amounts of all products reported by the medical institutions in the alliance area of ​​the same product group, and sort the amounts from high to low, ranking the top 3 applicants

If there are less than 3 declared companies entering the B competition unit, all the declared companies in the same product group will be merged into the A competition unit

Quotation request

Quotation representative product

Base price

Declared price

The shortlisting rules are still the familiar "double envelope" rules.
The shortlisted companies are generated based on the comprehensive scores of the quotation representative products and the recognition of medical institutions, corporate rankings, supply capabilities, innovation capabilities, recruitment credit rating, drug quality and safety, etc.

.

All the companies in the competition unit A of the 17 product groups will be ranked in descending order from highest to lowest.
The top 70% of the companies (rounded to the nearest whole number, the same below) will be directly eligible for the proposed selection; if the lowest level of decline is the same, then one And get the qualifications to be selected
.
The lower 30% of the companies in the ranking of the decline will enter the bargaining process and accept the median decline of the finalists in all A competition units of the 17 product groups (50% of the ranking decline, the same below), and obtain the qualification for the proposed selection
.

In the B competition unit, if the number of shortlisted companies is more than 4, the shortlisted companies will directly obtain the qualifications to be selected
.
If the number of shortlisted companies is less than or equal to 4, the price drop of the shortlisted companies will reach the lowest drop of the top 70% of the top 70% of the top-ranked companies in all A competition units of the 17 product groups, and they will be eligible for the proposed selection; those that have not reached the bargaining process will enter the bargaining process and accept 17 product groups The median rate of the shortlisted companies in all A competition units dropped and they were eligible to be selected
.

After determining the company to be selected according to the above rules, the applicant company that is not shortlisted or not selected, whose representative product is the lowest average daily treatment cost in the same product group, can be eligible for the selection
.
If the average daily treatment cost of the quotation representative product is the same, the one with the higher comprehensive score will be eligible to be selected
.